Introduction {#Sec1}
============

Since December 2019, the world is struggling against Coronavirus Disease 2019 (COVID-19) and in the past months, the life of more than one-third of the planet's population has radically changed \[[@CR1]\]. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has shown to be a very contagious virus potentially causing complicated atypical pneumonia and associated with significant mortality \[[@CR2]\]. Despite initially confined to Hubei province, China and Asia, COVID-19 promptly spread to western countries, and in March 11, 2020, the World Health Organization (WHO) declared a public health emergency of international concern \[[@CR3]\]. By early April, we are counting over 1,500,000 cases and 88,000 deaths worldwide, with 209 countries involved over 4 continents \[[@CR4]\]. Italy was one of the first western countries diagnosing COVID-19 patients in late January and was certainly the one suffering the most by the sudden outbreak of the disease. Indeed, SARS-CoV-2 rapidly spread throughout the country by the end of February, challenging the healthcare system toward its collapse, increasing the mortality rate and raising the question concerning the need for special measures to contain the crisis. As a matter of fact, by mid-March the Italian cases of COVID-19 were already 20,000 with almost 2000 patients requiring mechanical ventilation in the intensive care unit (ICU) \[[@CR5]\]. Consequently, the Italian Government announced extraordinary measures to contain the spread of the pandemic, by means of small confinements in northern Italy, reaching a nationwide lockdown that is still limiting the population \[[@CR6]\].

COVID-19 outbreak seriously stressed the healthcare system worldwide, with the urgent need of extra ICU beds, dedicated hospital paths, personnel training, and infection control measures \[[@CR7], [@CR8]\]. Care of diseases outside the COVID-19 has rapidly changed, and healthcare providers are currently adapting to maximize and properly allocate resources \[[@CR9]\]. Surgical activity has shifted to pursue only emergency and elective cancer cases as described in different specialties \[[@CR10]--[@CR13]\]. Furthermore, the big picture and the full impact is still unknown as its effects on economy, hospital infrastructure, healthcare strategy, and prognosis of oncologic patients \[[@CR14]\]. Indeed, people with cancer might suffer the most by this worldwide outbreak as the access to surgery is limited by the significant reduction in available resources, eventually influencing the decision making and the therapeutic allocation of patients \[[@CR15]\].

The Italian experience anticipated what the world is currently facing, and the measures for containment, the healthcare adaptations, and the changes in hospital practice have been already tested and are somehow established in our country where the peak of the infection seems to be reached and overcome \[[@CR5]\]. As the Italian National Institute for the Infectious Diseases, we have hospitalized the first Italian COVID-19 patients and since then, our general surgery department had to face this reality \[[@CR16]\]. The aim of this study was to demonstrate how our surgical activity was affected by the COVID-19 outbreak, what adaptations were made and how our practice changed, eventually sharing the lessons learned as anticipators in a health issue of international concern.

Materials and methods {#Sec2}
=====================

On January 31, two COVID-19-positive individuals were hospitalized at the Italian National Institute for the Infectious Diseases "L. Spallanzani" of Rome. In this hospital, four departments and five daily outpatient clinics are dedicated to the diagnosis and treatment of various infectious diseases. Health emergencies, such as SARS in 2003 and Ebola in 2014, have been nationally referred and managed at our hospital previously \[[@CR17], [@CR18]\]. In the same institution, our general surgery department operates in two daily operative rooms (OR) more than 900 cases per year, including liver, kidney, and pancreas transplantations. The ICU of the hospital admits both medical and surgical patients in a 9-bed department.

The records and official bulletins of our hospital were reviewed to retrieve the number of daily COVID-19 patients hospitalized, those requiring ICU admission and those discharged home. Furthermore, all the records of consecutive surgical procedures performed during the COVID-19 outbreak were reviewed, and the following data were extracted: age, gender, disease, comorbidities, neoadjuvant therapy, cirrhosis, previous surgery, type of surgical procedure, type of approach (open vs. laparoscopic), conversion, operative time, blood loss, and admission to the ICU. The search was limited between the nationwide lockdown (March 9, 2020) and April 24, 2020.

Informed consent was obtained from each patient, and every oncologic case was discussed in a multidisciplinary meeting involving surgeons, medical oncologists, gastroenterologists, radiologists, and pathologists.

Definitions {#Sec3}
-----------

Comorbidities were graded using the American Society of Anesthesiology (ASA) score, the Charlson Comorbidity index (CCI), and the Revised Cardiac Risk Index for Preoperative Risk (RCRI). Patients with a high probability of postoperative ICU admission were considered as high risk and defined by an ASA score ≥ III and/or a CCI ≥ 6 and/or a RCRI ≥ 3 as previously validated \[[@CR19]--[@CR21]\]. Major hepatectomies were defined as the resections of three liver segments or more \[[@CR22]\]. Pancreatic resections, total gastrectomies, major hepatectomies, and multivisceral resections as well as liver and kidney transplantations were considered as the high-risk surgical procedures because of the increased likelihood of postoperative ICU admission.

Statistical analysis {#Sec4}
--------------------

Distribution of variables was assessed using Kolmogorov--Smirnov and Shapiro--Wilk tests.

Data are expressed as the mean ± standard deviation for parametric continuous data and as median and interquartile ranges for non-parametric distribution. Categorical data were expressed as number and percentages. Categorical data are expressed as number and percentages. Chi-squared or Fisher exact test with Yates correction when appropriate was used to compare differences in categorical variables. Unpaired student's t-test was used to compare differences in continuous parametric variables and the Mann--Whitney test for continuous non-parametric variables. Statistical analysis was performed with SPSS software (version 20.0. Armonk, NY, IBM Corp) for MacOsX. A *p* value of \< 0.05 was considered statistically significant.

Results {#Sec5}
=======

Timeline of events since the hospitalization of the first COVID-19 patients in Italy {#Sec6}
------------------------------------------------------------------------------------

On January 31, 2020 (Day 0), the first two COVID-19-positive patients in Italy were admitted to the department of infectious diseases of our hospital with mild fever and atypical pneumonia requiring no invasive treatment. On February 4 (Day 4), due to the worsening clinical conditions, mechanical ventilation was needed, and the two patients were admitted to the ICU. Three days later (Day 7), a third patient with positive nasopharyngeal swab was admitted and monitored at the department of infectious diseases. From Day 4 to Day 30 (March 1, 2020), diagnostic nasopharyngeal swabs for symptomatic patients were implemented at our institution as part of a regional referral policy; however, no further patients tested positive to SARS-CoV-2, picturing a stable phase of the epidemic. On March 2 (Day 31), two individuals had a positive swab and were hospitalized; since then, an exponential growth of COVID-19 cases admitted to our hospital was registered as part of a national trend. Sixty-five hospitalized cases were reached on Day 34, nine of which required mechanical ventilation, therefore saturating the capacity of the ICU. On the evening of March 8, the Italian government announced the national lockdown, and the following day (Day 38), the first Institutional guidelines on extraordinary COVID-19 measures were released by our hospital (Fig. [1](#Fig1){ref-type="fig"}): (1) All healthcare workers were required to enhance hygienic measures and wear surgical masks and gloves within the hospital building. (2) Construction works in the ICU started with the aim of increasing the number of beds from 9 to 25. (3) One of our daily general surgery operating rooms was closed to reallocate anesthesiologists and nurses to the management of COVID-19 cases. (4) The OR personnel was trained on how to wear and un-wear special equipment and how to deal with contagious patients. (5) Our surgical department was asked to re-consider and re-work the OR planning to perform only oncological cases and transplantations; outpatient clinics were significantly reduced. (6) Questionnaires on possible infection or contacts with COVID-19 cases were administered to all patients admitted and scheduled for surgery; nasopharyngeal swabs were performed in suspicious cases. (7) All gatherings, including our multidisciplinary meetings, were forbidden and reworked on a webinar platform.Fig. 1Timeline of events in our hospital since Italian national lockdown

On March 23 (Day 52), further Institutional guidelines were released: (1) Relatives were forbidden to visit patients before and after surgery. (2) Nasopharyngeal swabs were administered to all patients admitted and scheduled for surgery and isolation was maintained until test's response. As a result, the first COVID-19 patient of our surgical ward was identified on Day 53: the man had a Klatskin tumor and was scheduled to receive a right hepatectomy with hepaticojejunostomy. Unfortunately, he was shifted to percutaneous transhepatic biliary drainage and transferred to the infectious disease department.

Surgical practice during COVID-19 {#Sec7}
---------------------------------

Seventy-two patients (47 males and 25 females) with a median age of 64 (53--74) were operated at our surgical department in the study period (Table [1](#Tab1){ref-type="table"}). Most patients had colorectal cancer (22.2%) and colorectal liver metastases (18.0%), followed by cholangiocarcinoma (11.1%) and pancreatic ductal adenocarcinoma (8.3%). Twelve patients (16.6%) had liver or kidney disease requiring transplantation and no patients died while on the waiting list. Compared to the same period of time in 2019, fewer procedures were performed in 2020 (72 in 2020 vs. 115 in 2019); furthermore, a statistical significant difference in terms of type of operations was found between years (23.4% benign, 73.9% malignant, and 2.6% transplantations in 2019 vs. 0% benign, 86.4% malignant, and 16.6% transplantations in 2020; *p* \< 0.001).Table 1Characteristics of patients operated during the COVID-19 outbreak (March 9--April 24, 2020)*n* = 72Age (years)64 (53--74)Gender F/M25/47Comorbidities19 (26.3%)ASA score1.9 ± 0.5Charlson Comorbidity Index3.7 ± 1.3Revised Cardiac Risk Index for Preoperative risk1.2 ± 0.6Previous surgery21 (30.5%)Cirrhosis9 (12.5%)Neoadjuvant systemic therapy12 (16.6%)High-risk patients16 (22.2%)Diagnosis Colorectal cancer16 (22.2%) Cholangiocarcinoma8 (11.1%) Colorectal liver metastases13 (18.0%) Hepatocellular carcinoma3 (4.1%) Pancreatic ductal adenocarcinoma6 (8.3%) Gastric cancer3 (4.1%) Renal clear cell carcinoma4 (3.6%) Sarcoma2 (5.5%) Adrenal cancer1 (1.3%) Gastrointestinal stromal tumor2 (5.5%) Other malignancy^a^2 (5.5%) HCV related liver cirrhosis2 (5.5%) HIV related liver cirrhosis1 (1.3%) Alcohol related liver cirrhosis1 (1.3%) NAFLD1 (1.3%) Autoimmune hepatitis1 (1.3%) Chronic kidney failure6 (8.3%)Data expressed as median and interquartile ranges or absolute count and percentages*ASA* American Society of Anesthesiology, *HCV* hepatitis C virus, *HIV* human immunodeficiency virus, *NAFLD* non-alcoholic fatty liver disease^a^One liver cistoadenocarcinoma, one suspicious malignant abdominal lymph node

Overall, patients operated during the COVID-19 outbreak had few comorbidities (26.3%), low ASA score (1.9 ± 0.5), CCI (3.7 ± 1.3), and RCRI (1.2 ± 0.6), being overall at lower risk of postoperative ICU admission (Table [1](#Tab1){ref-type="table"}). Furthermore, few patients had liver cirrhosis (12.5%) or received preoperative systemic therapy (16.6%). Type of surgical procedures and operative details are depicted in Table [2](#Tab2){ref-type="table"}. We have performed 36 (50.0%) high-risk operations in the study period of which 6 (8.3%) were liver and 6 (8.3%) were kidney transplantations. Despite this, few patients were admitted to the ICU (20.8%). One patient (1.3%) died during the study period (one hyperacute allograft dysfunction following liver transplantation for autoimmune hepatitis). Morbidity rate was 19.4% and five patients (6.9%) developed a major grade complication according to Clavien--Dindo.Table 2Type of surgical procedures and operative details of patients operated during the COVID-19 outbreak (March 9--April 24, 2020)*n* = 72High-risk surgical procedures36 (50.0%)Type of surgical procedure Colorectal resection^a^15 (20.8%) Major hepatectomy w/o hepaticojejunostomy14 (19.4%) Minor hepatectomy11 (15.2%) Pancreaticoduodenectomy6 (8.3%) Total gastrectomy1 (1.3%) Distal gastrectomy2 (2.7%) Nephrectomy2 (2.7%) Multivisceral resection2 (2.7%) Other malignant procedures^b^7 (9.7%) Orthotopic liver transplantation^c^6 (8.3%) Kidney transplantation6 (8.3%)Laparoscopic approach26 (36.1%)Conversion0 (0%)Blood loss (mL)400 (100--600)Operative time (min)390 (200--400)Patients admitted to the ICU15 (20.8%)*ICU*intensive care unit^a^Four right colectomies, nine left colectomies, and two anterior rectal resections^b^Two gastric wedge resections, one nephrectomy with removal of inferior vena cava a right atrium tumor thrombus, one partial nephrectomy, one adrenalectomy, one transanal endoscopic mucosectomy, and one abdominal lymph node biopsy^c^MELD score of patients at the time of liver transplantation: 28 (23--33)

Changes in surgical practice during the two phases of COVID-19 outbreak {#Sec8}
-----------------------------------------------------------------------

As mentioned above, during the first period (January 31--March 8, 2020), COVID-19 hospitalizations were stable at our hospital, with two cases admitted to the ICU and one monitored at the department of infectious diseases. In the second period (March 9--April 24, 2020), an exponential growth in number of admissions was registered, with a median of 10 (4--21) positive cases per day (Fig. [2](#Fig2){ref-type="fig"}). At the same time, a median of 3 (2--4) cases per day were operated by our surgical team in the first period, while fewer cases were operated in the second (median of 2 (1--2) per day; *p* = 0.001). Thirty-nine (41.9%) benign conditions, 48 (51.6%) oncological patients, and 6 (6.5%) transplantations were performed in the first period, while only malignant cases and transplantations (*n* = 72, 100%) were performed in the second.Fig. 2Number of COVID-19 patients per day and general surgery cases since the hospitalization of the first COVID-19 patients

Considering only the transplantations and the operations performed for cancer, patients in the second period had fewer comorbidities, lower ASA score, CCI, and RCRI, being overall at lower risk of postoperative ICU admission (Table [3](#Tab3){ref-type="table"}). Furthermore, fewer patients had previous surgery (30.5% vs. 57.4%; *p* \< 0.001) and/or received preoperative systemic therapy (16.6% vs. 48.1%; *p* \< 0.001). The number of high-risk operations was higher in the second phase of the pandemic (27.8% vs. 50.0%; *p* = 0.01). Despite this, fewer patients were admitted to the ICU in period 2 and this was statistically significant (37.0% in period 1 vs. 20.8% in period 2; *p* = 0.04).Table 3Characteristics of patients operated for malignancy according to the two phases of the COVID-19 outbreakJan 31--Mar 8 2020, *n* = 54Mar 9--April 24\
2020, *n* = 72*p*Age (years)64 (53--74)64 (53--77)0.38Gender F/M22/2625/470.22Comorbidities29 (53.7%)6 (21.4%)**0.001**ASA score2.3 ± 0.51.9 ± 0.5**0.004**Charlson Comorbidity Index5.1 ± 1.23.7 ± 1.3**\< 0.001**Revised Cardiac Risk Index for preoperative risk2.2 ± 0.71.2 ± 0.6**\< 0.001**Previous surgery31 (57.4%)21 (30.5%)**\< 0.001**Cirrhosis9 (16.7%)9 (12.5%)0.34Neoadjuvant systemic therapy26 (48.1%)12 (16.6%)**\< 0.001**High-risk patients25 (46.3%)16 (22.2%)**0.001**High-risk surgical procedures15 (27.8%)36 (50.0%)**0.01**Type of surgical procedure0.89 Colorectal resection7 (12.9%)15 (20.8%) Major hepatectomy w/o hepaticojejunostomy7 (12.9%)14 (19.4%) Minor hepatectomy12 (22.2%)11 (15.2%) Pancreaticoduodenectomy4 (7.4%)6 (8.3%) Distal pancreatectomy1 (1.8%)0 (0%) Esophagectomy1 (1.8%)0 (0%) Total gastrectomy1 (1.8%)1 (1.3%) Distal gastrectomy0 (0%)2 (2.7%) Nephrectomy3 (5.5%)2 (2.7%) Multivisceral resection1 (1.8%)2 (2.7%) Other malignant procedures11 (20.3%)7 (9.7%) Orthotopic liver transplantation3 (5.5%)6 (8.3%) Kidney transplantation3 (5.5%)6 (8.3%)Laparoscopic approach17 (31.4%)26 (36.1%)0.93Conversion1 (1.8%)0 (0%)0.63Blood loss (mL)165 (62--450)400 (100--600)0.77Operative time (min)381 (226--488)390 (200--400)0.12Patients admitted to the ICU20 (37%)15 (20.8%)**0.04**Data expressed as median and interquartile ranges or absolute count and percentagesBold reflects statistically significant results*ASA*American Society of Anesthesiology, *ICU*intensive care unit

Discussion {#Sec9}
==========

In this study, we have shown how the recent COVID-19 outbreak affected our department of surgery and transplantation. Fewer surgeries were performed and these were only for cancer and for urgent liver or kidney transplantations. Notwithstanding, we have maintained our standard practice by enhancing selection of patients, meanwhile allowing for the re-allocation of the hospital resources.

SARS-CoV-2 virus infection has dramatically changed the world recently. More than two hundred countries all over the world had to undertake extraordinary measures to contain the epidemic and reduce possible side effects on healthcare and economy \[[@CR1]\]. Indeed, many eastern and western governments followed the example of China and are currently in lockdown, with few exceptions. A deep impact was expected on the healthcare systems all over the world: re-allocation of resources was urgently required in an effort to contain the devastating consequences of the pandemic. As a domino effect, patients with other medical conditions, such as cardiovascular diseases, cancer, and chronic conditions, suffered and are still suffering as a collateral damage \[[@CR15]\].

In response to the rapid increase of COVID-19 cases, Institutional guidelines called for the re-arrangement of the hospital, shifting both infrastructures and personnel toward the containment of the infection and the management of SARS-CoV-2-positive patients. Anesthesiologists and nurses were re-allocated, and dedicated teams for both COVID-19 patients and surgical practice were created. Our department suffered the sudden closure of one daily OR and the significant reduction in the possibility to use ICU beds after surgery, as these were day by day used for the management of COVID-19 patients. As surgeons, we had to completely re-consider our roles and our surgical activity, reckoning with the limited resources. We had to face a healthcare emergency with uncertain future course and adapt accordingly. Surgeries for benign conditions were stopped and the waiting list for cancer was handled and reworked entirely. The most important limitation was the hampered access to the ICU as many patients require intensive monitoring after surgery for cancer, especially when major procedures are needed. Furthermore, we had to deal with the fact that transplantations normally require intensive care management in the postoperative. We were advised to limit the number of surgeries requiring ICU admission as much as possible, to avoid the saturation of resources and failure of the system. As an institutional policy, our transplant center remained opened and we decided to continue with our standard surgical oncology activity, improving selection of patients to limit the need for postoperative intensive care management. Waiting list for liver and kidney transplantations was maintained respecting the same inclusion and exclusion criteria and using the same prioritization. Transplantations were still admitted to the ICU for monitoring through a dedicated pathway with dedicated personnel, despite limiting their length of stay and discharging them to the surgical ward as soon as possible. Notably, we have performed standard numbers of the high-risk surgical procedures, selecting more surgically fit individuals. Furthermore, patients were less commonly having preoperative neoadjuvant chemotherapy and/or previous surgery, significantly lowering intraoperative risks. All the transplantations performed were admitted to the ICU, while only three oncologic patients required intensive care management after surgery: these latter were patients with significant comorbidities that were scheduled for the high-risk surgeries (two pancreaticoduodenectomies for adenocarcinoma and one right hepatectomy for hepatocellular carcinoma). Our policy was pursued in an effort to prioritize patients by cancer prognosis. Indeed, malignancies requiring high-risk surgical interventions (i.e., cholangiocarcinoma, liver metastasis, pancreatic adenocarcinoma, and sarcoma) are generally those with the worst prognosis and more likely to suffer by a delay in treatment \[[@CR23]\]. A different approach would have been to rework the waiting list for cancer prioritizing less-invasive procedures (i.e., colorectal resections) with no strict selection of candidates in order to cope with the limited resources \[[@CR24]\]. The main issue here is that both strategies will generate a gap in cure that has to be considered in the near future when the COVID-19 crisis will be over. Surgical delay should not affect oncological prognosis, in order to minimize future repercussions of this international health crisis \[[@CR23]\]. The alternatives to surgery and their efficacy should be reviewed and discussed for each type of cancer and case by case, in an effort to minimize the waiting list and the loss of patients due to cancer progression \[[@CR25], [@CR26]\]. In some cases, systemic treatment could be prolonged or adapted, while in others the window of cure might be missed; sometimes surgery can be postponed, while some other patients need surgical treatment to stay on their pathway \[[@CR27], [@CR28]\]. In this setting, multidisciplinary meetings should be reworked to consider patients with cancer in the COVID-19 era, in which resources and future are uncertain. Balancing the prognosis of cancer with the potential alternatives and the characteristics of patients might eventually lead to improve the treatment allocation exploiting resources and maintaining oncologic principles \[[@CR29]\]. Finally, an "hub and spoke" system based on a regional policy should be encouraged in the near future to allow for immediate referral and faster access to treatments, eventually improving quality of care.

Patients with cancer are paying the price at different levels, not only because of the limited access to cure but also because of the delay in diagnosis \[[@CR30]\]. Indeed, the significant reduction of outpatient clinics and the limitation in imaging modalities and/or endoscopies might hamper a rapid diagnosis and a prompt referral. As a further issue, it has already been shown that cancer patients are more susceptible to COVID-19 infections: 1% of COVID-19 patients in China had a history of cancer as compared to 0.29% among normal Chinese population \[[@CR2]\]. These patients were also having more severe infections and most commonly required intubation and invasive ventilation. One lesson that we have learned in our hospital is that the diagnostic modalities for COVID-19 are important not only to contain the infection and avoid the spread of the disease but also to ensure safe treatment of patients. Questionnaires are useless in our opinion, as we are at the point that this pandemic cannot be detected by recalling contacts or possible exposure to the infection \[[@CR31]\]. Indeed, once we have shifted to nasopharyngeal swabs for all patients admitted to our department, we had our first SARS-CoV-2-positive surgical candidate, this patient earlier tested negative to the questionnaire. On one hand, this highlights the importance of swabs for all surgical candidates to contain the infection among patients and healthcare workers; on the other hand, it sheds the light on the need for further evidence concerning the management of positive COVID-19 patients with cancer. Indeed, our patient with cholangiocarcinoma was shifted to non-surgical treatment: our team was unprepared at that time as no recommendations were available and issues regarding potential complications and transmission were raised. Recently, Lei et al. have demonstrated that 34 positive asymptomatic COVID-19 patients undergoing surgery had a 20% mortality rate, and all developed atypical pneumonias. Furthermore, it is very important to stress that our decision unfortunately altered the patient's prognosis, and this highlights the impact of this pandemic on our healthcare system. Finally, special considerations should also be made concerning COVID-19 transplanted patients \[[@CR32]--[@CR34]\]: indeed, immunosuppressive therapy might lead to an atypical clinical manifestation, such as unspecific viral disease or gastrointestinal symptoms \[[@CR35]\]. This should be taken into account in order to minimize unexpected clinical complications and unpredictable outcomes.

In our institution, we have recently standardized the use of PPE to limit the possible transmission of disease during surgery. It has been speculated that laparoscopy might increase transmission due to the aerosolized biological fluids \[[@CR36], [@CR37]\]. In line with this, we are now using extra protection (double gloves, shield, and filter mask) and filtered gas evacuation systems to avoid any possible transmission during minimally invasive procedures. However, as possible aerosolized fluids happen also as a result of cauterization during open surgery, the surgical community needs more evidence and guidelines concerning the proper use of equipment and resources to be used during surgery \[[@CR38]\].

This study has some limitations mainly being the retrospective analysis that might have introduced selection bias. In this setting, anesthesiologists could have decided subjectively whether the patient required ICU admission or not. Furthermore, as mentioned above, our hospital is a national referral for the infectious diseases and we have already faced previous emergencies \[[@CR17], [@CR18]\]; therefore, the rapid adaptation that we have shown in this manuscript could be the result of experience and competences gained over years.

Since the recent worldwide spread of the disease, many editorials, letters, and expert opinions have been published on COVID-19 crisis and many have speculated that surgical activity has suffered the spread of this pandemic \[[@CR12], [@CR14], [@CR23], [@CR39]--[@CR43]\]. To the best of our knowledge, this is the first manuscript presenting numbers and statistical analysis highlighting the changes in surgical practice during COVID-19 outbreak. As we write, Italy is already in its fourth week of lockdown, and the emergency seems to have reached the peak. We will be probably moving toward more relaxed containment measures despite a total opening is unlikely. Meanwhile, countries worldwide are facing the ascending phase of this outbreak with a delay of days or even weeks. We believe it is important to share our anticipatory experience on how we have changed and adapted our surgical practice to face this crisis and optimized resources. Future evolution of this infection is uncertain: evidence, policies, and recommendations may change on daily bases hopefully improving the quality of care and minimizing the side effects on more patients. We must be prepared to face the consequent need for care in the coming months. By then, a progressive inverse trend should be encouraged, reallocating resources to assist those who suffered the most by the outbreak, both re-enforcing diagnostic steps, and treatment possibilities to counteract the delay we have so far accumulated.

Conclusions {#Sec10}
===========

Besides the emergency of patients infected by SARS-CoV-2 infection, our healthcare system is facing the side effects of COVID-19 pandemic. Adjustments were necessary in many environments as well as in the surgical field. A shift toward the exclusive management of oncologic diseases and urgent cases has been recently recommended worldwide. Rearrangements of resources require adaptations in clinical practice. Multidisciplinary meetings should be reworked in the context of COVID-19 reality and selection of patients should be enhanced to ensure cure and minimize loss of patients. We foresee a difficult phase for the time being in which all the non-COVID 19 health issues will re-emerge. International cooperation is required, and resources should be allocated accordingly to better tackle this future emergency.
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